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Abstract
Background: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C
virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV.
Since our understanding of the HCV lifecycle would benefit from the identification of additional permissive cell
lines, we assembled a panel of hepatic and non-hepatic cell lines and assessed their ability to support HCV
infection. Here we show infection of the human hepatoma cell lines PLC/PRF/5 and Hep3B with cell culture-
derived HCV (HCVcc), albeit to lower levels than that achieved in Huh7 cells. To better understand the reduced
permissiveness of PLC and Hep3B cells for HCVcc infection, we performed studies to evaluate the ability of each
cell line to support specific steps of the viral lifecycle (i.e. entry, replication, egress and spread).
Results: We found that while the early events in HCV infection (i.e. entry plus replication initiation) are
cumulatively equivalent or only marginally reduced in PLC and Hep3B cells, later steps of the viral life cycle such as
steady-state replication, de novo virus production and/or spread are impaired to different degrees in PLC and
Hep3B cultures compared to Huh7 cell cultures. Interestingly, we also observed that interferon stimulated gene (i.e.
ISG56) expression was significantly and differentially up-regulated in PLC and Hep3B cells following viral infection.
Conclusions: We conclude that the restrictions observed later during HCV infection in these cell lines could in part
be attributed to HCV-induced innate signaling. Nevertheless, the identification of two new cell lines capable of
supporting authentic HCVcc infection, even at reduced levels, expands the current repertoire of cell lines
amendable for the study of HCV in vitro and should aid in further elucidating HCV biology and the cellular
determinants that modulate HCV infection.
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Background
Worldwide, between 130 and 170 million individuals are
chronically infected with h e p a t i t i sCv i r u s( H C V ) ,a
positive-strand RNA virus that infects the liver [1,2].
Although acute infection is typically asymptomatic,
~80% of patients fail to clear the virus resulting in a
chronic infection associated with the development of
significant liver disease, such as fibrosis, cirrhosis, stea-
tosis, insulin resistance and hepatocellular carcinoma
(HCC) [3]. In fact, HCV-related HCC accounts for over
50% of HCC cases and over 30% of liver transplants in
the United States. Despite this obvious public health
burden, there is no vaccine to prevent infection and
current interferon-based treatment options have toxic
side effects and limited efficacy.
The main obstacle that has impeded HCV research
and antiviral drug development since its discovery in
1989 [4] has been the lack of a robust infectious cell
culture system capable of recapitulating all aspects of
the viral lifecycle. Although early advancements in the
study of HCV were made using surrogate systems [5],
replicons [6-9] and HCV pseudotyped particles
(HCVpp) [10], it was not until the development of the
cell-culture derived HCV (HCVcc) system in 2005 that
robust HCV infection was finally achieved in vitro
[11-13]. This system was based on the identification of
an HCV genotype 2a molecular clone [14], shown to be
capable of replicating and assembling infectious particles
in cell culture, and the discovery that the human hepa-
toma Huh7 cell line is permissive for HCV infection.
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exist, only HepG2 cells and a few other hepatoma cell
lines have been rigorously tested for HCVcc permissive-
ness to date with varying degrees of success [11,15-20].
Identification of other cell lines able to support HCV
infection would not only expand our current repertoire
of cell lines available for the study of HCV, but could
also prove useful for the identification of cellular deter-
minants of HCV infection.
To identify other cell lines suitable for HCV infection
studies, we assembled a panel of hepatic and non-hepa-
tic cell lines and assessed their permissiveness for HCV
infection. Here we show HCVcc infection (i.e. replica-
tion, protein translation and de novo virion production)
in human hepatoma cell lines PLC/PRF/5 and Hep3B.
Like Huh7 cells, PLC cells, a human hepatoma cell line
first isolated in the early 1970s [21] and Hep3B cells, a
human hepatoma cell line derived from a hepatocellular
carcinoma isolated from an 8 year old male [22], have
been previously utilized for HCV entry (HCVpp)
[10,23-31] studies; however, to our knowledge, HCVcc
infection and RNA replication in these two cell lines in
the absence of complementation has not been previously
reported.
Results
Differences in permissiveness for HCVpp and HCVcc
among human hepatic and non-hepatic cell lines
Although numerous groups have assessed the permis-
siveness of multiple cell lines for HCVpp infection
[25,32], since the development of the HCV infectious
cell culture system [11-13] a comprehensive analysis of
the permissiveness of human hepatic and non-hepatic
cell lines for HCVcc infection has yet to be reported,
and the identification of alternate cell lines that support
robust HCVcc infection is still warranted. Thus, we
compiled a panel of human cell lines of hepatic and
non-hepatic origin (Table 1) that have been routinely
used for HCVpp entry [10,25,32,33] and assessed their
permissiveness for HCVcc infection.
First, for control HCVpp infections, cells were
infected with pseudotyped lentiviruses encoding a luci-
ferase reporter and bearing the glycoproteins E1 and
E2 of HCV genotype 2a (JFHpp), HCV E1 and E2 of
genotype 1a (H77pp) or the VSV G glycoprotein
(VSVGpp). At 72 h post infection (p.i.) pseudoparticle
entry was assessed by luciferase activity as previously
described [34]. All cell lines were equally permissive
for VSVGpp infection (8 × 10
5-9 × 10
5 RLU, data not
shown) however, only Huh7, Hep3B, PLC and HepG2
cells stably expressing CD81 (HepG2-CD81, Addi-
tional file 1: Figure S1) were permissive for HCVpp
infection (Figure 1A). All other cell lines tested exhib-
ited less than 1% of maximum luciferase activity, indi-
cating that these cells are non-permissive for HCVpp
entry, which is consistent with previously published
reports [10].
To assess permissiveness for HCVcc infection, all cells
were infected with HCVcc at an MOI of 2.0 FFU/cell
and intracellular HCV RNA was determined by
RTqPCR analysis 72 h p.i. We included Chinese ham-
ster ovary (CHO-K1) cells as they lack all known HCV
entry receptors and therefore serve as a control for
background HCV RNA levels (i.e. non-specific cell
bound HCV) (Figure 1B, dashed line = 10
2 copies/μg
RNA) [32]. As expected, Huh7 cells were highly per-
missive for HCVcc and replicated HCV RNA to levels
of 2.0 × 10
6 ±8 . 2×1 0
4 copies/μgR N Ab y7 2hp . i .
Caco-2 cell showed minimal to no HCVcc permissive-
ness, reaching levels of only 4.0 × 10
7 ±7 . 1×1 0
1
copies/μg RNA. Although Caco-2 cells have previously
been reported to support suboptimal HCVcc infection
[35], the low levels of HCV RNA (p value > 0.05) mea-
sured in these infected cultures are likely due to recep-
tor-bound HCV similar to that of the non-permissive
parental HepG2 cell line. Addition of CD81 to the
HepG2 cells conferred HCVcc permissiveness, as pre-
viously reported [11], resulting in increased HCV RNA
replication of 1.3 × 10
4 ±4 . 8×1 0
2 copies/μgR N A( p
value < 0.01). Notably, statistically significant HCVcc
infection was also detected in PLC cells and Hep3B
cells. Although PLC cells were less permissive for
HCVpp (Figure 1A), PLC cells contained 10-fold
higher HCV RNA levels (3.9 × 10
4 ±2 . 6×1 0
3 copies/
μg RNA) 72 h after infection with HCVcc compared to
Hep3B cells (2.8 × 10
3 ±3 . 5×1 0
2 copies/μgR N A )
(Figure 1B), which were as permissive as Huh7 cells
for HCVpp infection (Figure 1A). Taken together,
these data indicate that PLC and Hep3B cells are per-
missive for both HCVpp and HCVcc infection,
although their permissiveness for HCVcc and HCVpp
infection is reduced to different degrees compared to
Huh7 cells, suggesting that PLC and Hep3B cells may
differ in their capacity to efficiently support specific
Table 1 Summary of Cell Lines





Caco-2 Human epithelial colorectal adenocarcinoma
293T Human embryonic kidney epithelial
HeLa Human epithelial carcinoma
SW13 Human adrenocortical carcinoma
CHO-K1 Chinese hamster ovary
Sainz et al. Virology Journal 2012, 9:30
http://www.virologyj.com/content/9/1/30
Page 2 of 16aspects of the HCV lifecycle. Thus, we initiated experi-
ments to systematically dissect PLC and Hep3B per-
missiveness for HCVcc infection, focusing separately
on each step in the viral lifecycle.
PLC and Hep3B cells express all four HCV entry factors
and support HCVcc entry
PLC cells [21], Hep3B cells [22] and HepG2-CD81 cells
are hepatoma-derived cells lines which although differ
cytologically from one another share similar hepato-
cytes-like characteristics with Huh7 cells, such as cuboi-
dal epithelial-like morphology with high nucleus-to-
cytoplasm ratio, containing mono- and bi-nuclei with
multiple nucleoli and cytoplasmic granules (Additional
file 1: Figure S2). Our initial screening (Figure 1) indi-
cated that these three cells lines also share permissive-
ness for both HCVpp and HCVcc infection albeit to
differing degrees. Since viral binding/entry represents
the first step in the HCV lifecycle, we first assessed the
expression of the known HCV entry factors in these
cells by measuring CD81, SR-BI, CLDN1 and OCLN
mRNA levels by RTqPCR analysis (Figure 2A). When
compared to Huh7, no significant difference in mRNA
expression for the four known HCV entry factors was
observed among the four cell lines. We next analyzed
the cell surface expression of CD81 and SR-BI by flow
cytometry and CLDN1 and OCLN by indirect immuno-
fluorescence (IF) as our commercially-available antibo-
dies to these two tight junctions proteins are not
amendable to flow cytometric analysis. As shown in Fig-
ure 2B, cell surface expression of CD81 and SR-BI in
PLC, Hep3B and HepG2-CD81 cells, as measured by
flow cytometry, was comparable to that observed on
Huh7 cells. IF analysis of CLDN1 and OCLN also con-
firmed cell surface expression of these receptors on the
newly identified HCVcc-permissive PLC and Hep3B
cells as well as the previously characterized Huh7 [36]
and HepG2-CD81 cells [35]. Taken together, these data
indicate that PLC and Hep3B cells, at a minimum,
express and localize all four known HCV entry receptors
on their cell surface.
Despite expression all four of the previously estab-
lished essential HCV entry factors, the PLC and
HepG2-CD81 cells showed a reduced permissiveness
for HCVpp infection (Figure 1A) when compared to
Huh7 and Hep3B cells. While varying luciferase activ-
ity after parallel HCVpp inoculation is a phenotype we
have seen among Huh7 cell lines from different labora-
tories (Additional file 1: Figure S3 and [34]), to func-
tionally test whether these cells express suboptimal
levels of any of the known HCV entry factors, we tran-
siently transfected PLC, Hep3B and HepG2-CD81 cells
with vectors expressing the four known human HCV
receptors and reassessed their permissiveness for
HCVpp and HCVcc infection 48 h post-transfection.
As shown, expression of HCV entry factors in trans
individually (Figure 3) or in combination (data not
shown) did not enhance HCVpp (Figure 3A-C) or
Figure 1 Permissiveness of cell lines for HCVpp and HCVcc
infection.( A) Indicated cell lines were infected with equal amounts of
JFHpp, H77pp or VSVGpp. HCVpp entry (relative light units (RLU) ± SD
for triplicate samples determined 72 h p.i.) relative to Huh7-1 cells was
calculated by subtracting cell line specific background and mock-
control signals and then normalizing for cell line-specific VSVGpp entry
levels. Results are graphed as a percentage of entry achieved in Huh7-
1 infected cultures. (B) Indicated cell lines were infected with HCVcc at
an MOI of 2.0 FFU/cell. Intracellular RNA was collected 72 h p.i. and
HCV RNA was quantified by RTqPCR, normalized to GAPDH and is
displayed as HCV RNA copies/μg total cellular RNA (means ± SD for
triplicate samples). Significant increases in HCV RNA levels compared
to CHO cells (one-way ANOVA and Tukey’sp o s th o ct test) are
denoted as * p value < 0.001. Dashed line represents background
levels of non-specific bound HCV RNA.
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HepG2-CD81 cells. Hence, the 65% less luciferase
activity generated when PLC cells were inoculated with
HCVpp compared to Huh7 and Hep3B cells, is not
due to suboptimal expression of any of the 4 known
HCV entry factors.
PLC and Hep3B cells can support equivalent levels of
HCV RNA replication as Huh7 cells
Defects in post entry steps, such as reduced HCV RNA
replication, can negatively affect HCVcc infectivity
even if entry is achieved. Since both PLC and Hep3B
cells appear to be entry competent to reasonable
Figure 2 Expression of HCV entry factors in hepatoma cells lines.( A) Total RNA was extracted from Huh7, PLC, Hep3B and HepG2-CD81
cells and mRNA copies were determined by RTqPCR using standard curves comprised of DNA plasmids expressing the coding sequence of the
gene of interest. Absolute quantities were normalized to GAPDH and data are displayed as mRNA copies/μg total cellular RNA (means ± SD). (B-
C) Cell surface expression of HCV entry factors on Huh7, PLC, Hep3B and HepG2-CD81 cells was determined by flow cytometric analysis or IF. (B)
For flow cytometric analysis, cells were trypsinized and stained with mouse anti-CD81 or anti-SR-BI monoclonal antibodies and an anti-mouse
secondary antibody conjugated with PE. Shaded regions represent cells stained with a monoclonal mouse IgG control primary antibody and an
anti-mouse PE-conjugated secondary antibody. (C) For IF analysis, fixed cells were stained with antibodies specific for CLDN1 or OCLN and
counterstained with a species specific Alexa-555-conjugated secondary antibody. Indicated protein is red (Alexa 555) and nuclei are blue
(Hoechst). Magnification × 630; scale bar = 20 μm.
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ness for HCVcc infection compared to Huh7 cells may
be due to defects in HCV RNA replication. To deter-
mine their capacity to support HCV RNA replication,
PLC and Hep3B cells were transfected with HCV gen-
o t y p e2 as u b g e n o m i c( s g 2 a )r e p l i c o nin vitro-tran-
scribed RNA, and G418-resistant colony formation was
determined as has been previously described for Huh7
[37] and HepG2 cells [18]. HCV sg2a replicons could
be readily established in both cell lines; however, the
ratio of colony formation to μgo fin vitro-transcribed
RNA was considerably lower in both Hep3B and PLC
cells compared to Huh7 cells (Figure 4A). Since this
reduction could be attributed to differences in trans-
fection efficiency, we introduced HCV by an alternative
means in which PLC and Hep3B cells were infected
with medium from Huh7 cells replicating the full
length 2a (fl2a) HCV replicon that contains infectious
HCVcc capable of conferring G418 resistance to newly
infected cells if entry is achieved and replication is
established [38]. Unlike the results obtained following
transfection of PLC and Hep3B cells with sg2a RNA,
the number of G418-resistant colonies established in
both PLC and Hep3B cells infected with HCVcc
G418
was more comparable to that achieved in Huh7 cells
(Figure 4B), although a 65% reduction in Hep3B col-
ony formation was noted (p = 0.02). We next
expanded some of these G418-resistant sg2a and fl2a
PLC and Hep3B clones and quantified HCV RNA
levels in each clone to determine steady-state HCV
RNA replication levels achieved in each cell line.
RTqPCR analysis revealed relatively similar levels of
HCV sg2a RNA replication in all three cell lines, with
no significant difference (p value > 0.05) in mean HCV
RNA copies/μg intracellular RNA observed between
Huh7, PLC and Hep3B G418-resistant sg2a clones
(Figure 4C; 5.9 × 10
6 ±7 . 2×1 0
3 vs. 3.9 × 10
6 ±6 . 0×
10
5 and 6.7 × 10
6 ±2 . 4×1 0
6, respectively). Likewise,
no significant difference (p value > 0.05) in the levels
of intracellular HCV RNA in fl2a HCVcc
G418-estab-
lished clones was observed between Huh7, PLC and
Hep3B G418-resistant fl2a clones (Figure 4D; 4.5 × 10
6
±1 . 8×1 0
4 vs. 3.9 × 10
6 ±6 . 7×1 0
4 and 5.8 × 10
6 ±
1.4 × 10
6 HCV RNA copies/μg, respectively). Impor-
tantly, since G418-resistant colony formation following
HCVcc
G418 infection is dependent on both successful
Figure 3 HCVpp and HCVcc infection in PLC, Hep3B and HepG2-CD81 cells exogenously over expressing HCV entry factors. Huh7, PLC,
Hep3B and HepG2-CD81 cells transiently transfected with a vector control plasmid or expression plasmids expressing CD81, SR-BI, CLDN1 and/or
OCLN were infected with (A-C) equal amounts of JFHpp, H77pp or VSVGpp or (D-F) HCVcc at an MOI of 2.0 FFU/cell. HCVpp entry (following
background and mock-control signal subtraction) is expressed as relative light units (RLU) ± SD for triplicate samples determined 72 h p.i.
Intracellular HCVcc RNA was quantified by RTqPCR, normalized to GAPDH and is displayed as mean HCV RNA copies/μg total cellular RNA ± SD
for triplicate samples determined 72 h p.i.
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that similar numbers of G418-resistant colonies and
equal levels of HCV RNA replication were achieved in
both PLC and Hep3B, compared to Huh7 cells, would
indicate that despite individual differences in the effi-
ciency of HCV entry or HCV replication between
these cell lines together the cumulative efficiency of
HCVcc entry plus subsequent RNA replication is rela-
tively equivalent in PLC, Hep3B, and Huh7 cells, thus
allowing equivalent stable infection initiation events to
occur (i.e. fl2a colony formation). However, to rule out
the possibility that HCVcc
G418 infection could have
selected for a population of PLC or Hep3B cells with
enhanced efficiency for viral entry and/or replication,
we cured fl2a PLC and Hep3B replicon clones by IFN-
treatment and re-assessed their permissiveness for
HCVcc infection. As shown in Additional file 1: Figure
S4, none of the IFN-cured fl2a clones showed
enhanced permissiveness for HCVcc infection com-
pared to their parental control.
PLC, Hep3B and HepG2-CD81 cells are defective for de
novo HCVcc production
Thus far, our results indicate that cumulatively the early
events in HCV infection (i.e. entry plus replication
initiation) are equivalent or only marginally reduced in
PLC and Hep3B, respectively compared to Huh7 cells.
Therefore, the 1.5 and 3 log reduction in HCVcc permis-
siveness observed for the PLC and Hep3B cell lines,
respectively (Figure 1A), is likely attributable to a defect
(s) in a post replication step, such as assembly and/or
egress of de novo HCVcc. To monitor multiple rounds of
HCV infection and spread, which is dependent on HCV
assembly and egress, we performed a kinetic analysis of
HCV infection over the course of 7 days in Huh7, PLC,
Hep3B and HepG2-CD81 cells after infection with
HCVcc at a low MOI (Figure 5). Using this approach, we
show that intracellular HCV RNA levels (Figure 5A) in
Huh7 cells infected with HCVcc at an MOI of 0.1 FFU/
cell reached 4.44 × 10
3 ±4 . 8 4×1 0
2 copies/μgR N Ab y
one day p.i. and increased exponentially thereafter
~3,000-fold reaching a steady-state level of 1.6 × 10
7 ±
2.0 × 10
6 copies/μg RNA by day 5 p.i. HCV-infected PLC
cells showed parallel but slightly reduced HCV RNA
expansion kinetics during the first 48 h p.i. compared to
HCV-infected Huh7 cells; however, by day 3 p.i., HCV
RNA levels began to decline reaching undetectable levels
by day 7 p.i. In HCV-infected Hep3B cells, following a 1-
2 log increase in HCV RNA levels during the first 72 h p.
i., HCV RNA reached and maintained a low steady-state
l e v e lo f~ 2 . 1×1 0
3 ±6 . 9×1 0
2 copies/μg RNA. Similarly
HepG2-CD81 cells clearly lacked a notable robust expan-
sion in HCV RNA levels after 24 h p.i. and maintained a
low steady-state level (1.6 × 10
3 ±7 . 1×1 0
2 copies/μg
RNA) until day 7 p.i. Likewise, when entry was bypassed
by transfecting cells with infectious full-length HCV JFH-
1 in vitro-transcribed RNA, a similar profile of RNA
expansion and kinetics was observed (Additional file 1:
Figure S5).
Analysis of HCV-positive cells by immunocytochem-
ical staining of HCV E2 protein 5 days p.i (Figure 5B),
indicated that while the majority of cells in the Huh7
culture had become infected, only a small percentage of
the cells in the PLC, Hep3B and HepG2-CD81 cultures
were infected likely representing the 10% of cells that
where initially infected by the viral inoculum. Since viral
spread to a large extent is mediated by de novo secretion
of infectious HCV virions, we next quantified the level
of infectious HCVcc secreted into the supernatants of
each infected cell line over the course of 7 days (Figure
5C) using a standard HCV foci formation assay as
described [40]. While infectious HCVcc was detectable
in Hep3B and HepG2-CD81-infected cultures at
reduced levels, infectious HCVcc was undetectable (i.e.
below the lower limit of the assay) in the culture super-
natant of HCV-infected PLC cells even at day 2 when
the PLC cultures had amplified a higher level of intra-
cellular HCV RNA than the Hep3B and HepG2-CD81
cells (Figure 5C).
Figure 4 HCV sub-genomic and full-length replicon RNA
replication in PLC and Hep3B cells.( A) Huh7, PLC and Hep3B
cells were transfected with 1 μgo fin vitro-transcribed sg JFH-1 RNA
via electroporation. Cells were diluted 1:500 and plated in 100 mm
tissue culture dishes and maintained in the presence of 500 μg/ml
G418 for 2 weeks. Colonies were fixed, stained with crystal violet
and counted. (B) Huh7, PLC and Hep3B cells were infected with 100
FFU of HCVcc
G418 and maintained in the presence of 500 μg/ml
G418 for 2 weeks. Colonies were fixed, stained with crystal violet
and counted. (C-D) HCV G418-resistant sg and fl replicon clones
were expanded in the presence of 500 μg/ml G418 and total RNA
extracted ~3 weeks post expansion. HCV RNA was quantified by
RTqPCR, normalized to GAPDH and is displayed as mean HCV RNA
copies/μg total cellular RNA ± SD for each clone.
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HCVcc egress
To distinguish whether the lack of infectious HCVcc
present in the supernatant of HCV-infected PLC cells
(Figure 5C) is due to a defect in i) intracellular HCV
RNA encapsidation and virion assembly and/or ii)
release of de novo infectious HCVcc, we infected Huh7
and PLC cells with HCVcc at an MOI of 1.0 FFU, col-
lected cells and culture medium from infected cultures
over the course of 4 days, and quantified intracellular
and extracellular HCVcc infectivity titers and viral RNA.
Consistent with the data shown in the 7 day low MOI
infection experiment (Figure 5C), increasing infectious
HCVcc levels were detected in the supernatant of HCV-
infected Huh7 cells; however, at no time p.i. did we
detect infectious HCVcc in the culture supernatants
from HCV-infected PLC cells (Figure 6A). To determine
whether non-infectious HCVcc virions were secreted
from the infected PLC cells, supernatants were treated
with S7 Micrococcal nuclease, RNA extracted and HCV
genome copies quantified by RTqPCR. As shown in Fig-
ure 6B, extracellular nuclease-protected HCV RNA (i.e.
encapsidated viral RNA) was detected in culture super-
natant harvested from HCV-infected Huh7 cells, and
levels exponentially increased over the course of infec-
tion, consistent with the production and excretion of de
novo infectious HCVcc. In HCV-infected PLC cells,
however, significantly lower levels of nuclease-protected
HCV RNA were detected with a modest exponential
increase in total copies observed between days 1 and 3.
Notably, if the HCV RNA present in the PLC cell super-
natant did reflect infectious HCVcc, the level of infectiv-
ity (~ 1-2 FFU/ml) would be below the level of
detection in our titration assay (10 FFU/ml). Thus, we
can not conclude from this whether the low level of
HCV RNA secreted by PLC cells represents infectious
or non-infectious virions. To assess the presence and
infectivity of intracellular HCV virions, cells were
washed extensively with 1 × PBS, trypsinized, resus-
pended in 10% cDMEM, pelleted at 1,400 RPM for 5
Figure 5 HCVcc infection kinetics in hepatoma cells. Huh7, PLC, Hep3B and HepG2-CD81 cells were infected with JFH-1 HCVcc at an MOI of
0.01 FFU/cell. Culture supernatant and intracellular RNA were collected at the indicated times p.i. (A) Intracellular HCV RNA was analyzed by RT-
qPCR, normalized to GAPDH and is displayed as HCV copies/μg total RNA (means ± SD for triplicate samples). (C). On day 5 p.i., parallel cultures
of infected cells were fixed and stained for HCV E2 [39] (magnification, 100×). (C) Infectivity titers, expressed as FFU/ml, were determined on
naïve Huh7-1 cells. The dashed line represents the lower limit of detection of the assay (10
1 FFU/ml).
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freeze thaws. Cell debris was removed by centrifugation
and the presence of infectious HCVcc in cleared lysates
was determined by foci titration analysis and the pre-
sence of non-infectious HCV by RNA analysis following
S7 Micrococcal nuclease treatment. As expected,
increasing levels of infectious HCVcc and nuclease-pro-
tected HCV RNA were detected in intracellular lysates
from HCV-infected Huh7 cells over the course of infec-
tion (Figure 6C and 6D, respectively). In HCV-infected
PLC cells, low levels of infectious HCVcc were detect-
able only on days 3 and 4 p.i. (Figure 6C), and similar
to the levels of extracellular HCV RNA detected in cul-
ture supernatants (Figure 6B), low levels of nuclease-
protected HCV RNA were detected in intracellular
lysates, again with a modest exponential increase in
total copies observed between days 1 and 3. Together,
these data indicate that the ability of PLC cells to effi-
ciently encapsidate HCV RNA is markedly reduced
compared to Huh7 cells, resulting in low to undetect-
able levels of secreted infectious de novo HCVcc.
Non-Huh7 hepatoma cells induce the expression of IFN-
stimulated genes following HCVcc infection
Viruses often induce a cellular innate immune response,
mediated by the induction of IFN-stimulated genes
(ISG), in the infected host cell [41]. Although the cellu-
lar ISGs and pathways induced by viral infections are
generally similar among mammalian cells (reviewed in
[42]), different cell lines possess different abilities to
Figure 6 HCV extracellular and intracellular infectivity titers and RNA genome copies in Huh7 and PLC cells. Huh7 and PLC cells were
infected with JFH-1 HCVcc at an MOI of 1.0 FFU/cell. Culture supernatant and cells were collected at the indicated times p.i. (A) Extracellular
infectivity titers, expressed as FFU/ml, were determined on naïve Huh7-1 cells. The dashed line represents the lower limit of detection of the
assay (10
1 FFU/ml). (B) For extracellular RNA analysis, culture supernatant samples were treated with S7 Micrococcal nuclease prior to RNA
purification. Two μg of total murine carrier RNA was added to all samples for normalization. HCV RNA values were determined by RT-qPCR and
are displayed as HCV copies/μg total carrier RNA (means ± SD for triplicate samples). The dashed line represents the background of the assay
(10
1 HCV RNA copies/μg carrier RNA). (C-D) For intracellular infectivity titer and RNA analysis, cells were pelleted, re-suspended in complete 10%
cDMEM and lysed via multiple freeze/thaws. (C) Intracellular infectivity titers, expressed as FFU/ml, were determined on naïve Huh7-1 cells. The
dashed line represents the lower limit of detection of the assay (10
1 FFU/ml). (D) Intracellular HCV RNA copies were determined after S7
Micrococcal nuclease treatment by RT-qPCR and are displayed as HCV copies/μg total carrier RNA (means ± SD for triplicate samples). The
dashed line represents the background of the assay (10
1 HCV RNA copies/μg carrier RNA).
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which can potentially cause differences in permissive-
ness to viral infections. This has recently been demon-
strated by Zhao et al., for murine coronavirus infection
of different murine cell lines [43]. To determine if HCV
differentially induces the expression of ISGs in Huh7,
PLC, Hep3B and HepG2-CD81 cells following infection,
we evaluated ISG56 mRNA induction by RTqPCR fol-
lowing infection of cells with HCVcc at an MOI of 1.0
FFU/cell. As shown in Figure 7, ISG56 mRNA levels
were not up-regulated in HCV-infected Huh7 cells and
remained constant throughout the course of infection,
indicating that as previously shown [44], HCVcc does
not induce an efficient innate interferon response in
Huh7 cells. In contrast, induction of ISG56 was
observed in the other three human hepatoma cell lines
following HCVcc infection. Specifically, ISG56 mRNA
levels were up-regulated 3- and 2-fold in Hep3B and
HepG2-CD81 cells, respectively, as early as 24 h p.i. and
reached a steady state level by 3 days post infection.
The highest and most significant induction of ISG56,
however, was observed in HCV-infected PLC cells.
Notably, we have previously shown that IFN-mediated
activation of the innate cellular interferon response inhi-
bits HCV RNA replication and subsequent production
of de novo HCV virions ([45] and data not shown), thus
the reduced steady-state HCVcc infection levels
observed in Hep3B and HepG2-CD81 cells and the
decline of HCV infection observed in PLC cells, despite
these cells exhibiting comparable infection initiation
permissiveness, may be at least in part a consequence of
HCV-induced innate immune signaling in these hepa-
toma cell lines.
Discussion
In this study we characterized a panel of hepatic and
non-hepatic cell lines (Table 1) for HCVcc permissive-
ness. All non-hepatic cell lines were either refractory or
marginally permissive for HCVpp and HCVcc infection
(Figure 1), as previously shown [10,25,30,32,35]; how-
ever, contrary to commonly held perception, all three of
the hepatoma cell lines tested were permissive for
HCVcc infection, although to varying degrees relative to
Huh7 cells.
Permissiveness of hepatoma cell lines for HCVpp and
HCVcc infection
Considering the phenotypic differences observed among
the hepatoma cell lines (Additional file 1: Figure S2), the
perception that Huh7 cells are relatively unique in their
ability to support HCV infection [34,46], and based on
previous reports demonstrating varying degrees of
HCVcc infection in other hepatoma cell lines, such as
HepG2, HepaRG, and immortalized human hepatoma
(IHH) cells [15,16,18-20,32,47], we were surprised that
HCVcc infection and replication could be readily
detected in both Hep3B and PLC cells (Figure 1). In
fact, HCV RNA levels exceeding 10
4 copies/μgR N A
were detected in PLC cells 3 days post infection with
HCVcc. When compared direct l yt oH u h 7c e l l s ,h o w -
ever, it was apparent that HCVcc infection in both PLC
and Hep3B cells was reduced (2.0 × 10
6 ±8 . 2×1 0
4 vs.
3.9 × 10
4 ±2 . 6×1 0
3 and 2.8 × 10
3 ±3 . 5×1 0
2 copies/
μg RNA, respectively). In addition, our initial screen
also showed notable differences in permissiveness for
HCVpp infection between these two cell lines. Specifi-
cally, HCVpp infectivity was ~65% lower in PLC cells
compared to HCVpp-infected Huh7 and Hep3B cells.
However, although significant (p value = 0.03 and 0.02
for JFHpp and H77pp, respectively), we have seen simi-
lar variability in permissiveness for HCVpp infection
even among fully HCVcc-permissive Huh7 cell lines
from different laboratories (Additional file 1: Figure S3
and [34]), indicating that this level of HCV entry should
be sufficient to support robust HCVcc infection. Consis-
tent with this hypothesis, permissiveness for HCVcc
infection initiation was notably higher in PLC cells com-
pared to HCV-infected Hep3B cells (Figure 1B and 4B),
despite the lower permissiveness of the PLCs for
HCVpp entry (Figure 1A). Taken together, the results
from our initial screen (Figure 1) indicated that PLC
Figure 7 ISG56 mRNA induction in HCVcc-infected hepatoma
cells. Huh7, PLC, Hep3B and HepG2-CD81 cells were infected with
JFH-1 HCVcc at an MOI of 1.0 FFU/cell and intracellular RNA was
collected at the indicated times p.i. (A) Intracellular ISG56 mRNA
was analyzed by RT-qPCR, normalized to GAPDH and is displayed as
ISG56 mRNA copies/μg total RNA (means ± SD for triplicate
samples).
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and HCVcc infection; however, differences in permis-
siveness compared to Huh7 cells and between each cell
line do exist, and thus we initiated a systematic analysis
of PLC and Hep3B permissiveness for HCVcc infection,
performing experiments that focused on the different
steps of the viral lifecycle (i.e. entry, replication, egress
and spread).
i. HCV entry. To determine if the differences in
HCVpp and HCVcc infection between each hepatoma
cell line could be attributed to entry factors already
shown to modulate HCV permissiveness in other hepa-
toma cell lines [25,32,48-51], we examined the expres-
sion of four essential HCV entry factors (i.e. CD81, SR-
BI, CLDN1 and OCLN) by RTqPCR, flow cytometric
and immunofluorescence analysis (Figure 2). Interest-
ingly, the data indicated that when compared to the
fully permissive Huh7 cell line, no obvious differences in
m R N Al e v e lo rc e l ls u r f a c ee x p r e s s i o no fC D 8 1 ,S R - B I ,
CLDN1 or OCLN was observed in PLC, Hep3B or
HepG2-CD81 cells. In addition, we over-expressed each
of the four HCV entry factors in each cell line since we
and others have shown that expression of HCV entry
factors in trans can enhance HCVpp and HCVcc entry
in cells where HCV permissiveness is low [25,32,34].
Consistent with the observation that these cell lines
already express the necessary levels of the four HCV
entry factors, over-expression of CD81, SR-BI, CLDN1
or OCLN individually or in combination did not signifi-
cantly increase HCVpp or HCVcc entry in any of the
hepatoma cell lines (Figure 3). Hence, the current data
indicate that this panel of hepatoma cell lines expresses
the minimum set of known entry factors necessary for
efficient HCV entry. However, we cannot rule out the
possibility that the cells tested are deficient in another
HCV entry factor (e.g. the transferin receptor 1 protein
[52] or the Niemann-Pick C1-Like 1 cholesterol absorp-
tion receptor [53], which we recently showed to be
HCV entry factors), entry cofactors (e.g. epidermal
growth factor receptor and ephrin receptor A2 [54]) or
a post entry host cellular protein required for efficient
viral fusion or nucleocapsid uncoating.
ii. HCV RNA replication. To examine HCV replication
independent of inherent differences in PLC and Hep3B
cell transfection efficiency, we took advantage of the
G418-selectable HCVcc
G418 virus [38], which can be
used to establish HCV fl2a replicon cells via direct
infection of cells rather than electroporation. Using this
approach, 88, 77 and 52 G418-resistant colonies were
formed in Huh7, PLC and Hep3B cultures, respectively,
3 weeks following infection with 100 FFU of HCVcc
G418
(Figure 4B). Additional analysis of HCV RNA replication
levels in selected fl2a clones revealed that comparable
levels of HCV RNA replication were achieved in all
three cell lines (Figure 4D). Likewise similar levels of
intracellular HCV RNA were achieved in sg2a replicon
cell clones (Figure 4C). Importantly, since G418-resis-
tant colony formation following HCVcc
G418 infection is
dependent on both successful viral entry and efficient
HCV RNA replication, the fact that similar numbers of
G418-resistant colonies and equal levels of HCV RNA
replication were achieved in both PLC and Hep3B cells,
compared to Huh7 cells, indicate that the cumulative
efficiency of viral entry plus subsequent RNA replication
initiation is relatively equivalent between PLC, Hep3B
and Huh7 cells.
iii. Spread and infectious HCVcc production. By per-
forming a 7 day low MOI infection assay, we were able
to assess the efficiency of viral spread by assessing intra-
cellular HCV RNA expansion relative to de novo infec-
tious HCVcc production and by visualizing viral spread
directly by immunostaining for HCV-positive cells. Ana-
lysis of HCV RNA replication following infection of
each cell line with HCVcc (Figure 5A) or electropora-
tion with full-length infectious HCV JFH-1 in vitro-tran-
scribed RNA (Additional file 1:Figure S5) revealed that
while intracellular HCV RNA initially increased in all
the infected/transfected cell cultures at different rates, it
was only in Huh7 cultures where HCV RNA levels con-
tinued to increase exponentially past day 2 or 3 post
infection/transfection. Notably, exponential increase of
viral RNA in these cultures after day 2-3 p.i. would
require spread of the virus from the original infected/
transfected cells. Consistent with this, HCV E2 staining
on day 5 post-HCVcc infection revealed that the vast
majority of Huh7 cells were HCV-positive while little to
no spread was evident in the PLC, Hep3B or HepG2-
CD81 cell cultures (Figure 5B). Thus, while infection
could be initiated in all these cell lines, only Huh7 cells
appeared to support efficient viral spread. Since spread
of HCV to naïve cells following infection is dependent
on secretion of de novo infectious virions, we measured
infectious HCVcc in the supernatant of infected cultures
and observed detectable but reduced levels of infectious
HCVcc in Hep3B and HepG2-CD81 culture superna-
tants and undetectable levels of HCVcc in infected PLC
cultures (Figure 5C). Low steady-state levels of intracel-
lular HCV RNA and infectious virus production in the
Hep3B and HepG2-CD81 cells could result from a
defect/bottleneck in any phase of the viral life cycle (e.g.
reduced and/or ISG inhibition of entry, replication or
secretion); however, since the cumulative efficiency of
viral entry plus subsequent initiation of HCV RNA
replication appears to be relatively equivalent between
Hep3B, HepG2-CD81 and Huh7 cells (Figure 4B), it is
reasonable to speculate that robust HCV infection in
Hep3B and HepG2-CD81 cells may be limited by a
decreased capacity for virus production compared to
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was a clear and severe defect in HCVcc virus produc-
tion. Not only were no infectious particles detected in
the supernatant of infected cultures (Figure 5B and 6A),
but analysis of HCVcc present within the cell revealed
low to undetectable levels of intracellular infectious vir-
ions (Figure 6C) and comparably low levels of encapsi-
dated HCV RNA in both these extra- and intra-cellular
samples (Figure 6B and 6D) suggesting virion assembly
is restricted at or before genome encapsidation.
Cellular determinants of HCV permissiveness
The reduced ability of PLC, Hep3B and HepG2-CD81
cell cultures to support robust steady-state infection
levels or spread of HCVcc is likely multifactorial and
could be directly due to or influenced by the lack of suf-
ficient levels of a cellular protein necessary for efficient
production of infectious progeny virus or a consequence
of the presence of an inhibitory factor.
i. ISG induction. Since induction of innate immune
signaling can have negative affects on multiple steps in
the HCV lifecycle, we assessed the ability of PLC,
Hep3B and HepG2-CD81 cells to mount an innate
immune response against HCV infection by measuring
ISG56 mRNA induction, as a representative ISG, follow-
ing HCVcc infection. Importantly, while no induction of
ISG56 was observed in Huh7 cells, as previously pub-
lished [44], ISG56 mRNA was up-regulated in HCV-
infected PLC, Hep3B and HepG2 cells, with PLC cells
exhibiting the most significant induction following
HCVcc infection (Figure 7). Although it is generally
believed that most cultured hepatoma cells generally are
impaired for poly(I-C)- and virus-activated IFN
responses [55], these results are consistent with previous
findings that IFN-b promoter activity is more potently
induced in HepG2 and Hep3B cells than in Huh7 cells
following either liposome-mediated transfection of poly
(I-C) or Sendai virus infection [56]. Relevant to this, a
more recent publication by Marukian et al. [57] shows a
correlation between innate antiviral gene induction and
impaired HCV replication and spread in primary liver
cells. Likewise, HCV spread was not observed in highly
differentiated microscale primary human hepatocyte cul-
tures described by Ploss et al., (2010), who speculated
that while the expression of viral proteins in the initially
infected cells might be sufficient to blunt intracellular
antiviral signaling and allow sustained viral replication,
interferon produced by the infected cell may be suffi-
cient to signal to/activate adjacent naïve cells rendering
them resistant to infection and thus limiting subsequent
viral spread [58]. Thus, the differences in ISG induction
observed between these cells lines (Figure 7) may keep
HCV replication lower on a per cell basis (Hep3B and
HepG2-CD81) and/or at higher levels successfully
inhibit viral replication in the infected cells sufficiently
to contribute to clearance of the infection (PLC).
ii. miR-122. While ISGs are well known negative
determinants of HCV permissiveness, numerous positive
determinants required for efficient HCV replication
have also been identified (reviewed in [59]). Although
overlap between independent studies is not often
observed, leaving the relevance of many of these factors
to be confirmed, new data from multiple laboratories
has recently demonstrated that human micro RNA
(miR122) is a critical liver-specific factor required for
robust HCV infection and secretion [60-65]. Because
IFN treatment has been shown to reduce miR122
expression in Huh7 cells [66], it is possible that the
enhanced ISG induction observed in the other three cell
lines may more potently reduce this important positive
regulator of HCV infection. Likewise, miR122 has been
shown to play an important role in regulating choles-
terol homeostasis, fatty acid metabolism and lipogenesis
[63-65,67], three lipid metabolic pathways shown to be
necessary for HCV replication, assembly and secretion.
In fact, just prior to submitting this manuscript, Evans
and colleagues and Matsuura and colleagues separately
showed that exogenously expressing human miR122 in
HepG2 or Hep3B cells, respectively, results in robust
HCV replication and infectious virus secretion following
HCVcc inoculation or HCV RNA transfection [19,20].
Hence, lack of adequate miR122 may also contribute to
the reduced HCV permissiveness of certain cell lines.
In summary, by testing a panel of human hepatoma
and non-hepatoma cells for HCVcc permissiveness we
identified new cell lines capable of supporting authentic
HCVcc infection (e.g. entry, replication, protein expres-
sion and at least for Hep3B cells, de novo virion produc-
tion). The permissiveness of PLC and Hep3B cells for
HCVcc infection is clearly less robust than that achieved
in the highly HCVcc-permissive Huh7 cell lines [34]
and while further studies are needed to definitively and
quantitatively assess the host cell factors that limit HCV
infection in these cells, these two hepatoma cell lines
nonetheless provide new in vitro tools for elucidating
the cellular factors that control or mediate HCV infec-
tion, particularly those associated with HCV ISG induc-
tion or those involved in de novo HCVcc production
and secretion. In addition, HCV sub-genomic and full-
length replicons have not been previously established in
Hep3B and PLC cells [33]. Thus, the clones generated
in this study add to the current repertoire of sub-geno-
mic and full-length HCV replicons already available to
study specific aspects of the HCV life cycle such as
HCV polyprotein processing, replication complex forma-
tion and HCV RNA replication. Expanding our arsenal
of reagents and cell lines amendable for the study of
HCV should certainly advance our overall understanding
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involved, facilitating the potential development of new
and more specific HCV antivirals.
Methods
Cells and viruses
Huh7-1 cells have been previously described [34]. The
following cells were purchased from the American Type
Culture Collection: PLC/PRF/5 cells (CRL-8024), HepG2
cells (HB-8065), HeLa cells (CCl-2), SW13 cells (CCl-
105), and CHO-K1 cells (CCL-61). Hep3B and 293T
cells were kindly provided by Dr. Lijun Rong (University
of Illinois at Chicago, Chicago, IL) and Caco-2 cells by
Dr. Waddah Alrefai (University of Illinois at Chicago,
Chicago, IL). All human cell lines were cultured in com-
plete Dulbecco’sm o d i f i e dE a g l e ’sm e d i u m( D M E M )
( H y c l o n e ,L o g a n ,U T ) .C H O - K 1c e l l sw e r ec u l t u r e di n
Ham’s F-12 medium (Gibco Invitrogen, Carlsbad, CA).
Media was supplemented with 10% fetal bovine serum
(FBS) (Hyclone), 100 units/ml penicillin, 100 mg/ml
streptomycin, 2 mM L-glutamine (Gibco Invitrogen)
and in the case of HCV replicon cells 500 μg/ml G418
(Invitrogen).
JFH-1 cell culture-propagated HCV (HCVcc) viral
stocks were obtained by infection of naïve Huh7-1 cells
at a multiplicity of infection (MOI) of 0.01 focus form-
ing units (FFU)/cell, using medium from Huh7-1 cells
electroporated with in vitro-transcribed full length infec-
tious HCV JFH-1 RNA as previously described [40].
DNA constructs
The genotype 2a infectious JFH-1 (pJFH-1), the full
length (fl) JFH-1 replicon (pFLJFH) and the subgenomic
(sg) JFH-1 replicon (pSGJFH) plasmids were kindly pro-
vided by Dr. Wakita (National Institute of Infectious
Diseases, Tokyo, Japan) and have been previously
described [12,14,38]. The human CD81 (pEE6-huCD81),
human SR-BI (pZeo_hSR-BI), human CLDN1
(pZeo_CLDN1) and human OCLN (pCDNA3.1_OCLN)
expression plasmids have been previously described [34].
Pseudotyped retrovirus production and infections
Pseudotyped viruses were produced as previously
described [34]. Briefly, pseudotyped viruses were gener-
ated by co-transfection of DNA vectors encoding HCV
or vesicular stomatitis virus (VSV) envelope glycopro-
teins with an Env-deficient HIV vector carrying a luci-
ferase reporter gene (pNL4-3-Luc-R
--E
-)i n t o2 9 3 T
producer cells. The plasmids used for pseudotyped virus
generation have been described previously [34]. Super-
natants were collected 48 h post transfection, filtered
through a 0.45 μm-pore-size filter (BD Biosciences), ali-
quoted, frozen and subsequently titered using the
QuickTiter Lentivirus Titer Kit (Cell Biolabs, Inc., San
Diego, CA) according to the manufacturer’s instructions.
For infections, cells were seeded 24 h prior to infec-
tion in 96-well plates such that cell confluence at the
time of infection was 90%. Triplicate wells were inocu-
lated with equal titers of JFHpp, H77pp and VSVGpp
for 6 h, washed twice with 1 × PBS following infection,
and then overlaid with 200 μl cDMEM. At 72 h p.i. cul-
tures were lysed in 20 μl of lysis reagent to measure
luciferase activity (Promega, Madison, WI) using a
FLUOstar Optima microplate reader (BMG Labtechnol-
ogies Inc, Durham, NC). For all pseudotype virus experi-
ments presented herein, background-corrected (BC)
HCVpp RLU values were normalized to corresponding
BC-corrected VSVGpp RLU values: [(HCVpp-BC)/
(VSVG-BC)].
HCVcc infections
For infection of cell lines, each cell line was seeded 24 h
prior to infection in 96-well plates such that cell conflu-
ence at the time of infection was 90%. Triplicate wells
were inoculated with HCVcc at an MOI of 2.0 FFU/cell
and 72 h p.i. total cellular RNA was isolated for reverse
transcription followed by real-time quantitative PCR
analysis (RTqPCR). For low MOI HCV RNA kinetic
analysis, cells were seeded 24 h prior to infection in 6-
well plates such that cell confluence at the time of infec-
tion was 80%. Triplicate wells were infected with JFH-1
HCV at an MOI of 0.01 FFU/cell. During the 7 days
infection assay, infected cells were trypsinized before
reaching confluence and re-plated at a 1:3 dilution to
maintain active growth. At indicated times p.i., medium
and/or cellular RNA was harvested from triplicate wells
for titration or RTqPCR analysis, respectively.
RNA isolation and RTqPCR
Total intracellular RNA was isolated in 1 × Nucleic Acid
Purification Lysis Solution (Applied Biosystems, Foster
C i t y ,C A )a n dp u r i f i e du s i n ga nA B IP R I S M ™ 6100
Nucleic Acid PrepStation (Applied Biosystems), as per
the manufacturer’s instructions. Extracellular RNA from
cell supernatants or intracellular HCV RNA from lysed
cell pellets was treated with 4.5 units of S7 Micrococcal
nuclease (Fermentas, Glen Burnie, MD) for 30 min at
room temperature, and nuclease-treated RNA was iso-
lated by the guanidine thiocyanate (GTC) method using
1.6 × GTC containing 2 μg of murine total liver RNA
and following standard protocols [68]. One μgo fp u r i -
fied RNA was used for cDNA synthesis using the Taq-
Man reverse transcription reagents (Applied
Biosystems), followed by SYBR green RTqPCR using an
Applied Biosystems 7300 real-time thermocycler
(Applied Biosystems). Thermal cycling consisted of an
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cycles of denaturation (15 s at 95°C) and annealing/
extension (1 min at 60°C). HCV, human GAPDH, mur-
ine GAPDH, human CD81, human SR-BI, human
CLDN1, human OCLN and human ISG56 RNA levels
were determined relative to standard curves comprised
of serial dilutions of plasmids containing the JFH-1
HCV cDNA or the human GAPDH, murine GAPDH,
human CD81, human SR-BI, human CLDN1, human
OCLN and human ISG56 coding sequences, respec-
tively. The PCR primers used to amplify each respective
amplicon were: Universal HCV primers [69] 5’-GCC
TAG CCA TGG CGT TAG TA -3’ (sense) and 5’- CTC
CCG GGG CACTCG CAA GC-3’ (anti-sense), human
GAPDH [13] 5’-GAA GGT GAA GGT CGG AGT C-3’
(sense) and 5’- G A AG A TG G TG A TG G GA T TT C - 3 ’
(anti-sense), murine GAPDH [70] 5’-TCT GGA AAG
CTG TGG CGT G-3’ (sense) and 5’-CCA GTG AGC
TTC CCG TTC AG-3’ (antisense), human CD81 [25]
5’-ACC TCC TGT ATC TGG AGC TGG-3’ (sense) and
5’-TTG GCG ATC TGG TCC TTG TTG-3’ (anti-
sense), human SR-BI [25] 5’-TCG CAG GCA TTG
GAC AAA CT-3’ (sense) and 5’-CTC CTT ATC CTT
TGA GCC CTT TT-3’ (anti-sense), human CLDN1 [25]
5’- GTG GAG GAT TTA CTC CTA TGC CG-3’
(sense) and 5’- ATC AAG GCA CGG GTT GCT T-3’
(anti-sense), human OCLN [25] 5’-T C AA A CC G A
ATC ATT ATG CAC CA-3’ (sense) and 5’-A G AT G G
CAA TGC ACA TCA CAA-3’ (anti-sense), and human
ISG56 [71] 5’- GGG CAG ACT GGC AGA AGC -3’
(sense) and 5’- TAT AGC GGA AGG GAT TTG AAA
GC -3’ (anti-sense).
Flow cytometric analysis of cell surface receptors
Cells were resuspended in 150 μlo fF A C Sb u f f e r( 1×
PBS containing 2% (v/v) FBS, 0.3% (w/v) NaN3 and 1
mM EDTA) and incubated for 60 min at 4°C with a
1:100 dilution of antibodies specific for CD81 (AbD Ser-
otec) or SR-BI (BD BioSciences) Following three rinses
with FACS buffer, bound antibodies were detected by
incubation for 1 h at 4°C with an phycoerythrin (PE)-
conjugated anti-mouse (BD Pharmingen) antibody at a
dilution of 1:200. Cells stained with an irrelevant mouse
immunoglobulin G (IgG) antibody and respective PE-
conjugated secondary antibody served as negative con-
trols. Cells were washed three times, fixed in FACS buf-
fer containing 4% (w/v) PFA, and analyzed by flow
cytometry using the DakoCytomation CyAn system
(Dako, Carpinteria, CA) and Summit Software v4.3
(Dako).
Indirect immunofluorescence analysis
Cells were fixed with 4% PFA (Sigma, St. Louis, MO)
at indicated times and immunofluorescence analysis
was performed as previously described [36]. Briefly,
fixed cultures were rinsed three times with 1 × PBS,
permeabilized with 50% Methanol/50% acetone (v/v)
(Fisher) and subsequently blocked for 1 h with 1 ×
PBS containing 3% (w/v) bovine serum albumin (BSA)
(Sigma) and 10% (v/v) FBS. Cells were stained with a
1:750 dilution of a mouse anti-human CLDN1
(Abnova, Taipei, Taiwan) or mouse anti-human
OCLN (Zymed, San Francisco, CA) primary antibody
o v e r n i g h ta t4 ° C ,f o l l o w e d by incubation with a 1:750
dilution of an anti-mouse Alexa-555 conjugated sec-
ondary antibody (Molecular Probes) for 1 h at room
temperature. Cell nuclei were stained by Hoechst dye.
Bound antibodies were visualized via confocal micro-
scopy (630X, Zeiss LSM 510, Germany) and compared
to negative control samples stained with an irrelevant
mouse control antibody (Santa Cruz Biotechnology)
and Alexa-555 conjugated secondary antibody. Images
were analyzed using Zeiss LSM Alpha Imager Browser
v4.0 software (Zeiss), and brightness and contrast




HCV RNA transfection and G418-resistant colony
formation
HCV sg and fl 2a replicons were established as pre-
viously described [37]. Briefly, 1 μgo fin vitro-tran-
scribed HCV genotype sg2a or fl2a replicon RNA was
transfected into cells using a modified electroporation
protocol [72]. Transfected cells were diluted 1:500,
seeded in 100 mm tissue culture dishes and maintained
in the presence of G418 (Invitrogen) at a concentration
of 500 μg/ml until all cells died or distinct G418-resis-
tant cell colonies formed. To visualize colony formation,
cells were fixed with ethanol and stained with crystal
violet. Alternatively, colonies were expanded to establish
replicon cell lines. HCVcc
G418 was harvested from stable
fl 2a Huh7 replicon cells and infectivity titers were
determined as described below.
Infectivity titration assay and immuncytochemical
staining of HCV E2 protein
Culture supernatants were serially diluted 10-fold and
used to infect 96-well Huh7 cultures. At 24 h p.i., cul-
tures were overlayed with complete DMEM containing a
final concentration of 0.25% methylcellulose (Fluka Bio-
Chemika, Switzerland). Seventy-two hours p.i., cells
were fixed in 4% paraformaldehyde (Sigma), and immu-
nohistochemically stained for HCV E2 using a human
monoclonal anti-E2 antibody C1 [39] (a gift from Drs.
Mansun Law and Dennis Burton, The Scripps Research
Institute) as described [40]. Viral titers are expressed as
FFU/ml, determined by the average E2-positive foci
number detected at the highest HCV-positive dilution.
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To quantify intracellular HCVcc, HCV-infected cell cul-
tures were washed three times with 1 × PBS, trypsinized
for 5 min at room temperature and cells resuspended in 1
ml of 10% cDMEM. Cells were pelleted at 1,400 RPM for
5 min at 4°C, frozen and then thawed three times using a
95% ethanol:dry ice bath. Samples were then centrifuged
at 1,400 RPM for 5 min at 4°C to remove cell debris. The
supernatant fractions were used for titration of infectious
HCVcc or for HCV RNA analysis, as described above.
Statistics
Data are presented as the means ± standard deviation
(SD). Significant differences were determined by one-
w a ya n a l y s i so fv a r i a n c e( A N O V A )f o l l o w e db yT u k e y ’s
post hoc t test (GraphPad Prism
© Software).
Additional material
Additional file 1: Figure S1. Establishment of HepG2-CD81 cells. (A)
HepG2 cells, seeded in a 100 mm tissue culture dish, were transfected with
a vector control (left panel) or pEE6-huCD81 (right panel) using
Lipofectamine2000™™ according to the manufacturer’s instructions.
Twenty-four hours post transfection, cell culture medium was
supplemented with G418 at 500 μg/ml. Approximately 3 weeks post
transfection, G418-resistant colonies were trypsinized, pooled and cell
surface expression of CD81 was determined by flow cytometric analysis
using a mouse anti-CD81 antibody and an anti-mouse secondary antibody
conjugated with PE. (B) Cells expressing mean CD81 values of greater than
10
2 were sorted using a Becton Dickinson MoFlo cell sorter, expanded and
re-analyzed for cell surface CD81 expression by flow cytometry as described
above (Sort #1). (C) Cells expressing mean CD81 values of greater than 10
2
were sorted again, expanded and reanalyzed for cell surface CD81
expression by flow cytometry as described above. (Sort #2) Cells obtained
after two rounds of cell sorting were aliquoted, frozen and designated
HepG2-CD81 cells. Shaded regions represent cells stained with a
monoclonal mouse control primary antibody and respective anti-mouse PE-
conjugated secondary antibody. Additional file 1 Figure S2. Morphological
analysis of human hepatoma cell lines. (A) Huh7, (B) HepG2-CD81, (C)
Hep3B and (D) PLC cells were plated at 5 × 10
4 cells/well in a 12-well plate
and photographed 2 days after plating (magnification, ×100). Additional file
1 Figure S3. HCVpp infection of different Huh7 cell lines. Huh7 cells lines
from different laboratories [34] were infected with equal amounts of JFHpp,
H77pp or VSVGpp. HCVpp entry is expressed as relative light units (RLU) ±
sem for triplicate samples determined 72 h p.i. Additional file 1 Figure S4.
HCVcc infection of IFN-cured fl2a replicon clones. PLC and Hep3B fl2a
replicon cell lines replicating HCV RNA at levels ≥ 4.4 × 10
6 copies/μgR N A
were cured of HCV by co-treatment with 100 U/ml each of IFN-b and IFN-g
for 3 weeks. The absence of HCV RNA was confirmed by RTqPCR analysis.
Parental Huh7, PLC and Hep3B cells and cured fl2a replicon clones were
then infected with HCVcc at an MOI of 2.0 FFU/cell. Intracellular RNA was
collected 48 and 72 h p.i. and HCV RNA was quantified by RTqPCR,
normalized to GAPDH and is displayed as HCV RNA copies/μg total cellular
RNA (means ± SD for triplicate samples). wt = wild-type parental cells, C# =
clone number. Additional file 1 Figure S5. HCV RNA replication in Huh7, PLC,
Hep3B and HepG2-CD81 cells transfected with in vitro-transcribed full-
length infectious HCV JFH-1 RNA. Huh7, PLC, Hep3B and HepG2-CD81 cells
were transfected with 7 μgo fin vitro-transcribed full-length infectious JFH-1
RNA or a replication-deficient GND mutant via electroporation. HCV RNA
was quantified by RTqPCR on indicated days post-transfection, normalized
to GAPDH and is displayed as mean HCV RNA copies/μg total cellular RNA
±S D .
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